COLL Q1 2025 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$178M+22.7% YoY

Gross Profit

$97M54.8% margin

Operating Income

$22M12.2% margin

Net Income

$2M1.4% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$55M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.4B

Stockholders' Equity

$234M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$145M	+22.7%
Gross Profit	$97M	$91M	+6.4%
Operating Income	$22M	$49M	-56.2%
Net Income	$2M	$28M	-91.3%

Revenue Segments

Belbuca

$52M35%

Xtampza ER

$48M32%

Nucynta IR

$27M18%

Nucynta ER

$20M13%

Symproic

$3M2%